SecBot SecBot
3 ·Filed Apr 30, 2026

COAG

Hemab Therapeutics Holdings, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001231919-26-000435
Form 3, initial insider ownership statement
Actionable Insight • Neutral

This filing confirms RA Capital as a major pre-IPO holder with board representation. Monitor for an S-1 registration statement or IPO pricing announcement, as the conversion mechanics are tied to the IPO closing. The filing itself is routine and does not alter the current trading outlook.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$34.00
T+0 close · Apr 30, 2026 · via day close
Latest settled
+39.00%
T+60 · $47.26
Vs SPY
+35.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $34.00entry
  2. T+1 · 7mo ago −25.47%α −25.13% · $25.34
  3. T+5 · 6mo ago −26.12%α −28.46% · $25.12
  4. T+20 · 6mo ago −20.21%α −25.47% · $27.13
  5. T+60 · 4mo ago +39.00%α +35.93% · $47.26

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

RA Capital Management and affiliated entities filed Form 3 initial statements of beneficial ownership for Hemab Therapeutics (COAG), disclosing aggregate holdings of approximately 4.6 million shares of Common Stock on an as-converted basis from Series A, B, and C Preferred Stock. This is a routine initial ownership filing by a significant pre-IPO investor, confirming RA Capital's substantial stake ahead of a potential IPO.

Key Facts

  • RA Capital Management, L.P. and affiliated funds (RA Capital Healthcare Fund LP, Nexus Fund II, Nexus Fund IV) filed Form 3 initial ownership statements for Hemab Therapeutics.
  • RA Capital Healthcare Fund LP holds 1,422,960 shares of Common Stock (on as-converted basis from Series A Preferred).
  • RA Capital Nexus Fund II, L.P. holds 609,840 shares (Series A Preferred).
  • RA Capital Nexus Fund IV, L.P. holds 931,502 shares (Series B Preferred) and 1,253,384 shares (Series C Preferred).
  • Peter Kolchinsky and Rajeev M. Shah, managing members of RA Capital, are also reporting owners.
  • Dr. Laura Tadvalkar, a Managing Director of RA Capital, serves on Hemab's board of directors.
  • Preferred shares convert to Common Stock on a 22-for-1 basis immediately prior to the closing of the Issuer's initial public offering.

Financial Impact

RA Capital's aggregate beneficial ownership totals approximately 4,617,596 shares of Common Stock on an as-converted basis, representing a significant pre-IPO stake. No dollar amounts disclosed.

ownershipdilution

Risk Factors

  • No material financial or operational data disclosed; filing is purely administrative.
  • No indication of insider buying or selling activity beyond initial ownership reporting.

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001231919-26-000435
Document: 0001231919-26-000435-index.html0001231919-26-000435
Document: 0001231919-26-000435.txt0001231919-26-000435

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 7h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026